Inclusion Criteria:

          -  Histologically documented progressive squamous cell head and neck cancer with or
             without metastases, not amenable to curative treatment; or the patient has documented
             refusal of curative treatment.

          -  ECOG performance status of 0-2. Eastern Cooperative Oncology Group Performance Status:
             an attempt to quantify cancer patients' general well-being and activities of daily
             life. The score ranges from 0 to 5 where 0 is asymptomatic and 5 is death.

          -  Presence of measurable disease by CT scan per RECIST v1.1.

          -  Age ≥18 years.

          -  Life expectancy of ≥12 weeks.

          -  Women of childbearing potential must have a negative serum or urine pregnancy test at
             time of screening and confirmed within 3 days prior to treatment. Women not of
             child-bearing potential will be defined as all women older than age 50 and anovulatory
             for 12 months.

          -  Signed and dated informed consent document indicating that the patient (or legally
             acceptable representative) has been informed of all pertinent aspects of the trial
             prior to enrollment.

          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory
             tests, and other study procedures.

          -  Adequate organ and marrow function

        Exclusion Criteria:

          -  Previous treatment with cytotoxic chemotherapy therapy in the recurrent/metastatic
             setting. Previous treatment with non-cytotoxic agents in the recurrent/metastatic
             setting is permitted. Gastrointestinal abnormalities causing impaired absorption
             precluding administration of oral medications.

          -  Evidence of untreated or progressive brain metastases, spinal cord compression, or
             carcinomatous meningitis.

          -  A serious uncontrolled medical disorder or active infection that would impair their
             ability to receive study treatment.

          -  Dementia or significantly altered mental status that would prohibit the understanding
             or rendering of informed consent and compliance with the requirements of this
             protocol.

          -  Patients (male and female) having procreative potential who are not willing or not
             able to use adequate contraception. Women who are pregnant or breast-feeding.

          -  Patients residing in prison.

          -  Prior experimental therapy within 30 days of enrollment.

          -  Availability of curative treatment option for the patient's cancer, whether surgery,
             chemotherapy, radiation, or combination thereof, unless the patient has documented
             refusal of curative treatment.

          -  Current use or anticipated inability to avoid use of drugs that are known strong
             CYP3A4/5 inhibitors (atazanavir, boceprevir, conivaptan, clarithromycin, grapefruit or
             grapefruit juice, indinavir, itraconazole, ketoconazole, nelfinavir, nefazodone,
             posaconazole, ritonavir, saquinavir, telaprevir, telithromycin, voriconazole ).

          -  Current use or anticipated inability to avoid use of drugs that are known strong
             CYP3A4/5 inducers (carbamazepine, dexamethasone, fosphenytoin, phenytoin,
             phenobarbital, rifabutin, rifampin, rifapentine, St. John's wort).

          -  Patients with a history of severe allergic reaction to cisplatin or carboplatin